The GLP-1 receptor agonist exenatide failed to meet its primary outcome in a phase III trial of Parkinson's disease patients.

GLP-1 medications are renowned for their ability to treat type 2 diabetes and aid weight loss. Now, there's a new benefit to ...

Ozempic has been approved to reduce the risk of worsening kidney disease and cardiovascular death in adults with Type 2 ...

Chronic kidney disease affects about 37 million adults in the United States and is expected to rise. It is a common ...

The trial revealed that Ozempic® 1 mg significantly lowered the relative risk of worsening kidney disease, kidney failure, and cardiovascular death by 24% compared to a placebo, in addition to ...